Navigation Links
China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option
Date:12/31/2009

HONG KONG, Dec. 31 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the underwriters of its recent public offering of common stock have exercised a portion of their over-allotment option, which will result in the issuance of an additional 314,867 ordinary shares. The option was granted in connection with the public offering of 3,305,786 ordinary shares at a public offering price of $6.05 per share, which closed on November 24, 2009. The closing of the over-allotment issuance is scheduled for Tuesday, January 5, 2010 and will bring the total gross proceeds of the public offering to $21.9 million. China Cord Blood Corporation intends to use the net proceeds from the offering for the expansion into new geographical markets, including applications for new licenses and acquisitions and investments, and for the construction and upgrading of facilities in existing geographical markets.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. ( RODM) acted as lead Manager of the offering and Macquarie Capital acted as co-manager for the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This offering has been conducted solely by means of a prospectus supplement and accompanying prospectus relating to the offering of common stock can be obtained by contacting Rodman & Renshaw, LLC, 1251 Avenue of the Americas, New York, NY 10020, or by calling 212-430-1710. An effective registration statement relating to these securities has been filed with the Securities and Exchange Commission.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and the largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with more than one license (i.e., Beijing and Guangdong). Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only six licenses have been issued as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information about China Cord Blood Corporation, please visit: http://www.chinacordbloodcorp.com.

Forward-looking Statements

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in the People's Republic of China, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.


    For more information, please contact:
    China Cord Blood Corporation
    Ms. Joeling Law
    Phone: +852-3605-8180
    Email: ir@chinacordbloodcorp.com

    ICR, Inc.
    In the United States:
    Ashley M. Ammon or Christine Duan
    Phone: +1-646-277-1227
    In China:
    Wei-Jung Yang
    Phone: +86-10-6599-7968

SOURCE China Cord Blood Corporation

RELATED LINKS
http://www.chinacordbloodcorp.com

'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
2. American Oriental Bioengineering Announces the Inclusion of 158 Drugs in Chinas National Insurance Catalog
3. China Sky Medical, Inc. Has 30 Medicines that will Be Included in Chinas National Insurance Directory
4. China Biologic Products to Ring NASDAQ Opening Bell
5. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
6. Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit
7. Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies
8. China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia
9. China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List
10. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
11. China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit Business News ranks the ... evaluates the patent estate of a company, its impact and significance, and the likelihood ... the way in technologies that transform energy sources such as low dose X-ray and ...
(Date:1/12/2017)... ... January 12, 2017 , ... After ... Lisa Rosendahl’s doctors gave her only a few months to live. Now a ... that has stabilized Rosendahl’s disease and increased both the quantity and quality of ...
(Date:1/12/2017)... and Pune, India , January 12, 2017 ... Toxicity Testing Market by Type and End Users - Global Opportunity Analysis and Industry ... million by 2022 from $2,921 million in 2015, growing at a CAGR of 15.07% ... ... Allied Market Research Logo ...
(Date:1/11/2017)... Colo. (PRWEB) , ... January 11, 2017 , ... ... the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent ... despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated ...
Breaking Biology Technology:
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
(Date:12/20/2016)... , Dec. 20, 2016 The ... sharing, rental and leasing is stoking significant interest ... radio frequency technology, Bluetooth low energy (BLE), biometrics ... as the next wave of wireless technologies in ... access system to advanced access systems opens the ...
Breaking Biology News(10 mins):